Viridian Therapeutics, Inc.

VRDN

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001590750

SEC filings (opens in a new tab)

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of VRDN: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	138	2	165	+29
Shares	69.6M	4.77M	87.0M	+22.1M (+34.0%)
Value	$906.2M	$62.1M	$1.98B	+$1.14B (+134.5%)

2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (45)

Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to VRDN in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	4,804,006	$109.3M	0.00%
Driehaus Capital Management LLC	1,991,490	$45.3M	0.39%
EcoR1 Capital, LLC	1,958,847	$44.6M	1.53%
Adage Capital Partners GP, L.L.C.	1,205,000	$27.4M	0.05%
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	633,090	$14.4M	2.00%
Cutter Capital Management, LP	518,677	$11.8M	3.48%
Ikarian Capital, LLC	499,977	$11.4M	3.53%
Parkman Healthcare Partners LLC	425,000	$9.67M	1.23%
Lord, Abbett & Co. LLC	391,958	$8.92M	0.03%
Balyasny Asset Management LLC	339,089	$7.71M	0.02%
Integral Health Asset Management, LLC	250,000	$5.69M	0.67%
Exome Asset Management LLC	174,400	$3.97M	2.68%
Panagora Asset Management Inc	168,433	$3.83M	0.02%
Atika Capital Management LLC	167,000	$3.80M	0.41%
Crestline Management, LP	152,542	$3.47M	0.20%
Boothbay Fund Management, LLC	146,749	$3.34M	0.11%
D. E. Shaw & Co., Inc.	138,067	$3.14M	0.00%
Sphera Funds Management Ltd.	86,094	$1.96M	0.32%
Prelude Capital Management, LLC	51,050	$1.16M	0.09%
Cubist Systematic Strategies, LLC	50,898	$1.16M	0.02%
International Assets Investment Management, LLC	19,997	$879.0K	0.00%
Tudor Investment Corp Et Al	37,261	$847.7K	0.01%
Point72 Asset Management, L.P.	34,627	$787.8K	0.00%
PDT Partners, LLC	33,475	$761.6K	0.07%
Y-Intercept (Hong Kong) Ltd	29,002	$659.8K	0.04%
American Century Companies Inc	28,050	$638.1K	0.00%
Scientech Research LLC	26,860	$611.1K	0.12%
Intech Investment Management LLC	18,566	$422.4K	0.00%
Mesirow Financial Investment Management, Inc.	16,350	$372.0K	0.01%
Engineers Gate Manager LP	13,987	$318.2K	0.01%
Altfest L J & Co Inc	13,512	$307.0K	0.04%
ProShare Advisors LLC	11,823	$269.0K	0.00%
Connor, Clark & Lunn Investment Management Ltd.	9,130	$207.7K	0.00%
AJOVista, LLC	8,817	$200.6K	0.86%
Point72 Asia (Singapore) Pte. Ltd.	6,543	$148.9K	0.03%
Aster Capital Management (DIFC) Ltd	4,756	$108.2K	0.02%
Signaturefd, LLC	1,000	$22.8K	0.00%
Simplex Trading, LLC	911	$20.0K	0.00%
National Bank of Canada	100	$2.27K	0.00%
Sterling Capital Management LLC	100	$2.27K	0.00%
Bessemer Group Inc	85	$2.00K	0.00%
Wolff Wiese Magana LLC	38	$865	0.00%
Fortitude Family Office, LLC	38	$865	0.00%
Parallel Advisors, LLC	28	$637	0.00%
J.Safra Asset Management Corp	14	$327	0.00%

Sold out (16)

Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of VRDN in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Polar Capital Holdings Plc	889,198	$11.6M
RTW Investments, LP	605,816	$7.88M
Rosalind Advisors, Inc.	300,000	$3.90M
Acuta Capital Partners, LLC	199,433	$2.59M
Alyeska Investment Group, L.P.	100,000	$1.30M
J. Goldman & Co LP	74,985	$975.6K
Caption Management, LLC	44,300	$576.3K
Belvedere Trading LLC	28,720	$373.6K
Capstone Investment Advisors, LLC	21,016	$273.4K
Nebula Research & Development LLC	18,897	$245.8K
Bridgefront Capital, LLC	15,709	$204.4K
Alpine Global Management, LLC	13,794	$179.5K
UBS Oconnor LLC	10,057	$130.8K
EntryPoint Capital, LLC	5,569	$72.5K
Pacer Advisors, Inc.	825	$10.7K
Headlands Technologies LLC	596	$7.75K

Not filed for Q3 2024 yet (2)

Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VRDN in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	4,773,622	$62.1M
Institutional & Family Asset Management, LLC	18	$234